Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR p.Glu746Gly (p.E746G)
(
ENST00000455089.5,
ENST00000275493.7,
ENST00000450046.2 )
EGFR p.Glu746Gly (p.E746G) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study. Progression-free (415 days) and overall (462 days) survival suggested sensitivity in this patient. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1787
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/724
- Rating
- 1
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Erlotinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26773740
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erlotinib | Sensitivity | true |